For follow-up, studied subjects will be evaluated monthly to deliver capsules and to check for dietary adherence. Treatments will be administered during three months and the follow-up will continue throughout six months. At the end of the follow-up it is expect that the D+O3 group will present: a) higher decreases in mean weight and BMI, b) greater decreases in the mean fasting insulin concentration, HOMA index, and IR frequency, c) longer duration of weight lost.